Articles related to MYELOMA

Join this crucial journey to broaden your comprehension of CAR T-cell therapy, CRS and ICANS management, and learn how to utilize this knowledge for better patient outcomes in the battle against relapsed/refractory multiple myeloma.

Cilta-cel CAR-T-cell therapy: A ray of hope for refractory multiple myeloma patients. A new study on ciltacabtagene autoleucel CAR-T-cell therapy (cilta-cel) shows promise for relapsed/refractory multiple myeloma (RRMM) patients. Published in Blood, the study led by Dr. Adam Cohen from the University of Pennsylvania, focuses on patients with previous exposure to noncellular anti-B-cell maturation antigen (BCMA) therapies. The team’s objective was achieving the primary endpoint of minimal residual disease (MRD) negativity, alongside multiple secondary endpoints. They tested on patients above 18 with RRMM, progressive disease within 12 months of their last treatment or six months of prior therapy, and measurable disease at baseline. They conducted a multicohort study, primarily focusing on cohort C which entailed cilta-cel treatment. A total of 20 patients met the eligibility criteria and received cilta-cel. Among them, 35% had BsAb as their latest anti-BCMA treatment, while 65% had ADC. With a median follow-up of 11.3 months, 7 patients achieved MRD negativity. The overall response rate stood at 60%, with 55% achieving very good partial response (VGPR) or better, and 30% achieving complete remission (CR) or better. However, all patients experienced treatment-emergent adverse events, majorly grade 3 to 4 cytopenias. Most of these cytopenia events recovered to […]

This article reviews the novel CXCR4 inhibitor motixafortide and its use in hematopoietic stem-cell mobilization. We present a history of stem-cell mobilization and update of recent innovations in novel mobilization strategies. Hematopoietic stem-cell mobilization is a crucial step in autologous stem-cell transplantation. Motixafortide is a novel CXCR4 inhibitor that has been shown in preclinical and clinical trials to mobilize hematopoietic stem cells (HSCs) for transplantation. The drug has extended in vivo activity (>48 h) and high affinity (Ki, 0.32 nM). In a phase 1, two-part study, motixafortide administered to healthy subjects was safe, well tolerated, and led to a rapid and robust increase in the number of circulating HSCs. Motixafortide has been evaluated in a randomized phase 3 trial for autologous transplantation in multiple myeloma. The study showed that the combination of motixafortide and granulocyte colony-stimulating factor (G-CSF) was superior to G-CSF alone in terms of the number of CD34+ cells collected and the time to engraftment. The drug has also been evaluated in combination with plerixafor, another CXCR4 inhibitor, in a phase 1/2 study for autologous transplantation in multiple myeloma. The study showed that the combination of motixafortide and plerixafor was safe and effective in mobilizing HSCs. Motixafortide has […]

The authors evaluated the treatment approaches and outcomes of 110 patients with primary plasma cell leukemia (pPCL) in this retrospective study . Higher complete response rates were associated with treatment with bortezomib, lenalidomide, and dexamethasone (VRd) or daratumumab-based quadruplets (DBQ) and autologous stem-cell transplantation. Patients who received VRd/DBQ had better outcomes than those who received other bortezomib-based combinations or standard chemotherapy.

The article reports that a new blood test, called the EasyM protocol, has been certified by the US Food and Drug Administration (FDA) for use in detecting multiple myeloma relapse. The test works by detecting small amounts of circulating tumor DNA (ctDNA) in the blood, which can indicate the presence of residual disease. The EasyM protocol is reportedly more sensitive than existing tests for detecting ctDNA, and can provide results in just a few hours. The article notes that the test has the potential to improve patient outcomes by allowing for earlier detection of relapse and more personalized treatment options.

Following participation in this educational activity, hematologists/oncologists, nurses, pharmacists, cell therapy experts, and other HCPs actively involved in the care of patients with multiple myeloma should be better able to: